US › Healthcare

Fennec Pharmaceuticals Inc (FENC)

US · Healthcare · Biotechnology

$10.78+2.18%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$17.9M

Revenue YoY

+85.2%

Net profit

$2.0M

EPS

$0.05

EPS estimate

$0.01

Net margin

11.0%

EPS came in at 0.05 against a street estimate of 0.01 — a beat of 400.0%.

Key statistics

Market cap

$384.3M

Forward P/E

10.9

P/B

9.04

Book value

$1.21

EPS (TTM)

$-0.12

52-week high

$13.25

52-week low

$5.65

50-day MA

$11.08

200-day MA

$8.71

Beta

1.10

Analyst view

Analysts rate Fennec Pharmaceuticals Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $17.67.

Shareholding

Insiders

14.12%

Institutions

54.33%

Largest institutional holders

Fund	Stake
Rosalind Advisors, Inc.	8.29%
AIGH Capital Management, LLC	7.09%
Solas Capital Management LLC	7.08%
BlackRock Inc	3.90%
Vanguard Capital Management, LLC	2.56%
Awm Investment Company Inc	2.05%
Prospect Capital Advisors, LLC	1.42%
Geode Capital Management, LLC	1.06%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Fennec Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.